NCT06956144Recruiting
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
Source: ClinicalTrials.gov · Last updated 29 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 113 (estimated)
- First submitted
- 25 Apr 2025
- Start date
- 9 May 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Diseases
- Kidney cancer
- NCT number
- NCT06956144
What you commit to
- Study type: Observational
- Planned participants: 113
- From 9 May 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute systemic diseases and electrolyte imbalances.
Age
- Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).
Other
- Patients or their legal representatives who are unable or unwilling to sign the informed consent form.
- Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).
- Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.
Who the study is looking for
- Voluntary participation with the patient or their legal representative able to sign the informed consent form.
- Adult patients (age between 18 and 75 years), regardless of gender.
- Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).
- Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.
- ECOG performance status score of 0-3.
- Laboratory parameters must meet the following criteria:
- ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.
- Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L.
- Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.
Age in the registry: 18 years to 74 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000 Coordinator of this site? Confirm its status | Xiamen | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.